NCT04689594终止3 期
A Phase III, Multicenter, Open-label Study to Evaluate the Esophageal Stenosis Inhibition Effects and Safety of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group
适应症
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- Proportion of subjects without stenosis
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of esophageal epithelial regenerative treatment by the transplantation of the product, CLS2702C, to the esophageal wound site after extensive ESD for superficial esophageal cancer in the steroid administration risk group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who plan to undergo ESD for the treatment of superficial esophageal cancer
- •Patients aged >=20 years at the time of consent
- •Patients with no clinical metastasis (cN0M0) by cervical to abdominal CT
- •Patients with an endoscopically diagnosed depth of wall invasion remaining in the epithelium (EP) or lamina propria mucosae (LPM)
- •Patients with a tumor diagnosed as >=50% and <100% of circumference, and with prediction that resection circumference will be >=75% and <100%.
- •Patients with a tumor the major axis is <=50 mm, and with prediction that a major axis of a resection will be <=80 mm.
- •If the patient has multiple lesions, the circumference of all minor lesions other than the one lesion with the largest circumference (major lesion) must be <50%. However, if it is predicted that the major axis of the mucosal defect is >80 mm due to treating the major and minor lesions and assembling ulcers after the treating, the patient is excluded.
- •Patients with squamous cell carcinoma (including high-grade intraepithelial neoplasia) as confirmed by biopsy
- •Patients whose lesion is confirmed to be localized in the thoracic esophagus (lesions in the cervical esophagus or abdominal esophagus will be excluded). The location of the lesion will be determined by endoscopy.
- •Patients who have not received pretreatment for esophageal cancer. Treatment by ESD for superficial esophageal cancer for which the depth of wall invasion has been assessed to remain in the epithelium (EP) or lamina propria mucosae (LPM) is not included in the definition of pretreatment. However, patients who have a scar due to previous ESD in the major or minor lesions will be excluded from the study.
- •Patients with an ECOG Performance Status (PS) of 0 or 1
- •Patients in whom a commonly used endoscope with a tip diameter of 8.9 mm can pass
- •Patients with a dysphagia score of 0
- •Patients whose laboratory values within 28 days before enrolment meet all of the following criteria:
- •White blood cell count: >=4,000/microL
- •Platelet count: >=100,000/microL
- •AST: <=100 IU/L
- •ALT: <=100 IU/L
- •Total bilirubin: <=2.0 mg/dL
- •Serum creatinine: <=2.0 mg/dL
- •Patients who have received sufficient explanation about the study and provided written voluntary consent.
- •Patients who meet any of the following criteria:
- •With fibrous nodule shadow on IGRA negative diagnostic imaging
- •Required continuous systemic administration of immunosuppressants
- •With diabetes with blood glucose level of 180 mg/dL or more 2 hours after meal even with insulin
- •With 7.0% or more of hemoglobin A1c (HbA1c, (International standard value (NGSP value)) even if taking 2 or more drug treatments for more than 3 months
- •With high blood pressure which does not reach the target value even if taking 2-3 antihypertensive drugs or reach it with 4 or more antihypertensive drugs
- •With glaucoma, posterior capsule cataract or herpes simplex keratitis (Ophthalmology consultation is not mandatory)
- •With a risk of administration of corticosteroids based on medical judgment.
排除标准
- •Patients with cardiac disease (myocardial infarction, unstable angina, and heart failure), renal disease (nephrotic syndrome and kidney failure)
- •Patients who have an active (within 1 year) malignancy other than esophageal cancer
- •Patients with active bacterial, fungal, or viral infection
- •Patients who are being treated with a corticosteroid except for topical corticosteroids (ointments and creams) and oral ointments or patches used for treating stomatitis after oral mucosal tissue taken from D-16 to D-
- •Patients who are positive for any of serological test (HBs antigen, HBc antibody/HBs antibody, HCV antibody, HIV-1/2 antibody, HTLV-1 antibody, syphilis treponema antibody) or nucleic acid amplification test (HBV-DNA, HCV-RNA, HIV-RNA). However, this does not apply if the HBs antibody is positive and HBV-DNA is negative and the reason is clear that he was vaccinated with the hepatitis B vaccine.
- •Patients with a mental disorder that is difficult to control
- •Pregnant women, lactating women, and potentially pregnant women
- •Patients who have participated in another clinical study within 6 months, those who are participating in another clinical study, and those who plan to participate in another clinical study during participation in this study
- •Patients from whom tissues cannot be collected due to a disease (e.g., stomatitis, erosion, mass, and blister) in the oral mucosa at the tissue collection site
- •Patients with a history of hypersensitivity to antibiotic preparations (ampicillin sodium, sulbactam sodium, streptomycin sulfate, gentamicin sulfate, or amphotericin B) or who have taken drugs that may affect the study (within 28 days before enrolment)
结局指标
主要结局
Proportion of subjects without stenosis
时间窗: 24 weeks after endoscopic
Proportion of participants without stenosis until 24 weeks after endoscopic submucosal dissection (ESD)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Human (Autologous) Oral Mucosal Cell Sheet Transplantation After ESD in Patients With Superficial Esophageal CancerSuperficial Esophageal CancerNCT02866019CellSeed Inc.10
终止
不适用
An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of RefluxGastroesophageal Reflux Disease (GERD)Reflux, GastroesophagealAcid RefluxGastroesophageal RefluxNCT02749071EndoStim Inc.161
已完成
2 期
Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell CarcinomaEsophageal CancerNCT00815308Shandong Cancer Hospital and Institute55
招募中
2 期
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCESCC or Esophageal Adenosquamous CarcinomaNCT05221658Shanghai Henlius Biotech60
已完成
3 期
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) InfectionHepatitis C Virus InfectionNCT03074331Gilead Sciences130